Novoeight FDA Approval History
FDA Approved: Yes (First approved October 15, 2013)
Brand name: Novoeight
Generic name: turoctocog alfa
Dosage form: for Intravenous Injection
Company: Novo Nordisk
Treatment for: Hemophilia A
Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated for use in adults and children with hemophilia A.
Development timeline for Novoeight
|Oct 16, 2013||Approval NovoEight (turoctocog alfa) Receives Approval from the FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.